Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
13. November 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
29. Juli 2024 07:35 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the signing of a co-promotion agreement with Kowa Pharmaceuticals America, Inc.
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
29. Juli 2024 07:30 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
22. Juli 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis will host a KOL virtual event July 29, 2024
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
09. Juli 2024 16:53 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
01. April 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
11. März 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer.
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
09. März 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
04. März 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the closing of its previously announced underwritten public offering.
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
04. März 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.